Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Smoking Cessation Intervention in Respiratory Inpatients
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- General Hospital of Kavala
- Target Recruit Count
- 101
- Registration Number
- NCT02922387
Varenicline for "Gradual" vs. "Abrupt" Smoking Cessation in Low-motivated COPD Smokers
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 250
- Registration Number
- NCT02894957
Varenicline Treatment for Cannabis Use Disorder
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 72
- Registration Number
- NCT02892110
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Smoking Relapse Prevention Among COPD Ex-smokers
- Conditions
- Interventions
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- University of Auckland, New Zealand
- Target Recruit Count
- 8
- Registration Number
- NCT02888444
- Locations
- 🇳🇿
National Institute for Health Innovation, University of Auckland, Auckland, New Zealand
Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 122
- Registration Number
- NCT02859142
- Locations
- 🇺🇸
Clinical Addictions Research Laboratory, Chicago, Illinois, United States
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 23
- Registration Number
- NCT02856581
- Locations
- 🇺🇸
Baptist Health Paducah, Paducah, Kentucky, United States
🇺🇸Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States
🇺🇸Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States
Smoking Cessation & Opioid Dependence Treatment Integration
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 74
- Registration Number
- NCT02854800
- Locations
- 🇺🇸
West Virginia University Chestnut Ridge Center, Morgantown, West Virginia, United States
Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT02797587
- Locations
- 🇷🇺
First St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation
Effect of Smoking Cessation on Clinical and Microbiological Outcomes of the Non-surgical Periodontal Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Claudio Mendes Pannuti
- Target Recruit Count
- 63
- Registration Number
- NCT02744417
Combining Varenicline and Naltrexone for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 165
- Registration Number
- NCT02698215
- Locations
- 🇺🇸
UCLA Addictions Laboratory, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.